Enfusion CEO – Thomas Kim (Age – 52)

Note: Thomas Kim served as CEO of Enfusion from March 2020 to August 2022. He resigned in August 2022 and was succeeded by Oleg Movchan, who became permanent CEO in December 2022. Enfusion was subsequently acquired by Clearwater Analytics (NYSE: CWAN) in April 2025 for $1.5 billion. Thomas Kim is currently the CEO of Zone & Co, a global SaaS company.

Enfusion was a Chicago-based cloud-native investment management software company that provided a unified platform for portfolio management, order management, risk analytics, and accounting to hedge funds and institutional investors worldwide. In March 2020, fintech veteran Thomas Kim was appointed Chief Executive Officer of Enfusion, bringing more than two decades of experience in capital markets and financial technology. Under his leadership, Enfusion went public on the New York Stock Exchange (NYSE: ENFN) in October 2021, raised $150 million from ICONIQ Growth, and scaled its annual recurring revenue past $150 million. Kim resigned in August 2022 to spend more time with his family.

Read on to discover former Enfusion CEO Thomas Kim’s email address, net worth in 2026, salary and compensation, career history, education, and more.
Enfusion CEO Thomas Kim
Thomas Kim, Former CEO of Enfusion • Photo: Enfusion Inc.

Enfusion Competitors

Enfusion operated in the highly competitive investment management software and technology sector. Before its acquisition by Clearwater Analytics, the key competitors of Enfusion included:

  • Bloomberg AIM – scalable investment operations platform with portfolio accounting and data management
  • Charles River Development (State Street) – front-to-back investment management solution for large asset managers
  • SS&C Eze Software – order management and portfolio accounting suite for hedge funds
  • SS&C Advent – portfolio management, trading, and reporting tools for investment firms
  • SimCorp (Deutsche Börse) – integrated investment management solutions for asset managers
  • Clearwater Analytics (NYSE: CWAN) – cloud-based investment accounting and reporting (now Enfusion’s parent company)
  • Limina – modern cloud-native investment management system
  • Broadridge Financial Solutions – technology-driven solutions for the financial services industry

Thomas Kim – Quick Facts

Thomas Kim — At a Glance
Full Name Thomas Kim
Position Former Chief Executive Officer, Enfusion Inc.
Company Enfusion Inc. (formerly NYSE: ENFN; acquired by Clearwater Analytics)
Current Role CEO, Zone & Co (since May 2023)
Age ~52 years (as of 2026)
Education B.S. Business Administration, American University (Kogod School of Business)
Net Worth (Est.) $7–15 Million
Total Compensation (Enfusion) ~$4.1 Million (FY2021)
CEO Tenure March 2020 – August 2022
Email [email protected] (former)
Twitter/X @tkimny

Thomas Kim Net Worth 2026 – Enfusion CEO Salary

As of 2026, Thomas Kim’s net worth is estimated at approximately $7–15 million USD. His net worth is derived primarily from Enfusion stock holdings (approximately 897,870 shares as of his last SEC Form 4 filing in June 2022), his accumulated compensation as CEO, and his current earnings as CEO of Zone & Co. During his tenure at Enfusion, Kim oversaw the company’s 2021 IPO at $17.00 per share, at which point his stake was valued at approximately $15.3 million. When Clearwater Analytics completed its acquisition of Enfusion in April 2025 at $11.25 per share, the per-share value of his remaining holdings was approximately $10.1 million before taxes.

Enfusion CEO Compensation Breakdown (FY2021)

Component Amount (USD) Share
Base Salary $650,000 15.8%
Stock Awards $2,800,000 68.1%
Non-Equity Incentive $325,000 7.9%
Other Compensation $340,000 8.3%
TOTAL (Est.) ~$4,115,000 100%
Key Insight: Thomas Kim’s base salary at Enfusion was approximately $650,000 per year, inferred from his severance payment of $325,000 (six months’ base salary) upon his August 2022 resignation. The majority of his compensation was equity-based, reflecting Enfusion’s rapid growth trajectory through and after its October 2021 IPO.

Enfusion Net Worth – Company Financials

Enfusion was a profitable, high-growth SaaS company. In its final full fiscal year as a standalone public company (FY2024), Enfusion reported total revenue of $201.6 million, up 15.5% year-over-year, and served 916 clients across the globe. The company maintained a gross margin of 67.8% and generated an Adjusted EBITDA margin of 21.2%. In April 2025, Clearwater Analytics completed its acquisition of Enfusion for approximately $1.5 billion.

Enfusion Financial Summary (FY2024 – Final Year as Public Company)

Metric Value YoY Change
Acquisition Value $1.5 Billion
Annual Revenue $201.6M ▲ 15.5%
Annual Recurring Revenue (ARR) $210.4M ▲ 13.6%
Net Income $2.8M ▼ vs. $9.2M
Gross Profit Margin 67.8% ▲ 80 bps
Adjusted EBITDA Margin 21.2% ▲ 310 bps
Net Dollar Retention 103.0% ▲ 0.9 pts
Total Clients 916 ▲ Growing
NYSE Ticker (Delisted) ENFN Acquired Apr 2025
Acquisition Milestone: Clearwater Analytics (NYSE: CWAN) completed its $1.5 billion acquisition of Enfusion on April 21, 2025. Shareholders received $11.25 per share ($5.85 in cash + $5.40 in CWAN stock), creating the industry’s first single-instance, cloud-native platform unifying front-to-back investment operations.

Contact Enfusion CEO – Email Address | Twitter | LinkedIn

Below are the contact details and social media profiles for Thomas Kim. Note that his Enfusion email is no longer active following his departure in August 2022. He can be reached through his LinkedIn profile or Twitter/X account:

Contact Information
Email (Former) [email protected] (no longer active)
Twitter/X @tkimny
LinkedIn linkedin.com/in/thomas-kim-969960
Enfusion HQ (Former) 125 South Clark Street, Suite 750, Chicago, IL 60603
Current Company Zone & Co – zoneandco.com

Career & Education – Company, University, & College

Thomas Kim’s career spans over 25 years in capital markets and financial technology. He has held leadership roles at some of the most recognized names in fintech and institutional finance, consistently driving innovation in trading technology and investment infrastructure.

Thomas Kim Career Timeline

Period Role Company
2005–2006 Senior Executive TradingScreen
2006–2008 Senior Executive Lehman Brothers
2009–2012 Chief Executive Officer The UNX Companies
2012–2019 COO, Investment Engine Group Bridgewater Associates
2019–2020 Chief Executive Officer Tassat
2020–2022 Chief Executive Officer Enfusion Inc. (NYSE: ENFN)
2023–Present Chief Executive Officer Zone & Co

Before joining Enfusion, Thomas Kim served as CEO of Tassat, a blockchain-based digital payments platform, from 2019 to 2020. Prior to that, he spent seven years at Bridgewater Associates, the world’s largest hedge fund, where he served as Chief Operating Officer of the Investment Engine Group from 2012 to 2019. He was CEO of The UNX Companies from 2009 to 2012, a technology-driven agency brokerage. Earlier in his career, he held senior roles at Lehman Brothers (2006–2008) and TradingScreen (2005–2006).

At Enfusion, Kim led the company through a transformative period, including its October 2021 NYSE IPO (raising $367 million) and a major $150 million growth investment from ICONIQ Growth. He expanded the platform’s global footprint across nine offices on four continents before resigning in August 2022.

Since May 2023, Kim has served as CEO of Zone & Co, a global SaaS company that provides cloud-based ERP solutions built natively on Oracle NetSuite. Under his leadership, Zone & Co experienced nearly 50% revenue growth in 2023 and welcomed over 1,500 new customers.

Education

University Degree / Program Website
American University, Kogod School of Business Bachelor of Science in Business Administration kogod.american.edu

Thomas Kim Wiki – Age, Family, & More

Thomas Kim (age approximately 52 as of 2026) is a first-generation Korean-American technology executive. He has spoken publicly about how he views the American Dream not as a pursuit of material wealth, but as “a mentality; a drive to find happiness and peace in one’s self by persevering through challenges.” He credits the sacrifices his immigrant family made for his success and considers his family to be his greatest inspiration.

Kim is married and has cited his wife as someone he deeply admires for her empathy, compassion, and kindness. He draws wisdom and calmness from his father, strength from his mother, and diversity of thinking from his brothers. His decision to resign from Enfusion in August 2022 was motivated by a desire to spend more time with his family. He keeps most personal and family details private.

Notable Achievements

  • Enfusion IPO (2021) – Led Enfusion to a successful NYSE listing in October 2021, raising $367 million at a $17/share offering price
  • ICONIQ Growth Funding – Secured $150 million strategic growth investment from ICONIQ Growth for Enfusion in 2021
  • Revenue Growth at Enfusion – Under his leadership, annual revenue grew from $79.6 million (2020) to $150.4 million (2022), an 89% increase
  • Zone & Co Turnaround – Led nearly 50% revenue growth and 1,500+ new customers at Zone & Co in 2023
  • Bridgewater COO – Headed the Investment Engine Group at the world’s largest hedge fund for seven years (2012–2019)

As a leader, Kim champions the principles of meritocracy and transparency. He prefers keeping things simple to achieve ambitious organizational goals. In a well-known interview, he shared that if he could have a superpower, it would be the ability to control time, because “nobody ever has enough of it.”

About Enfusion

Enfusion was a cloud-native investment management software company founded in 1997 and headquartered in Chicago, Illinois. The company provided a unified, multi-tenant SaaS platform that combined portfolio management, order management, risk analytics, and managed services into a single solution, primarily serving hedge funds, family offices, and institutional asset managers globally.

Product / Service Description
Portfolio Management System (PMS) Real-time portfolio analytics, P&L, and exposure management
Order Management System (OMS) Multi-asset trade execution and compliance workflows
Risk Management Real-time risk analytics, stress testing, and scenario analysis
Managed Services Middle- and back-office outsourcing including accounting and reconciliation

Enfusion went public on the NYSE in October 2021 under the ticker ENFN, serving over 900 investment managers from nine global offices (Chicago, New York, London, Hong Kong, Singapore, Mumbai, Bengaluru, and more). Major institutional investors included FTV Capital, ICONIQ Growth, and Hillhouse Capital. On April 21, 2025, Clearwater Analytics (NYSE: CWAN) completed its $1.5 billion acquisition of Enfusion, and ENFN was delisted from the NYSE. The combined entity now offers the industry’s first single-instance, cloud-native front-to-back investment management platform.

Frequently Asked Questions (FAQ)

Who is the CEO of Enfusion?

Enfusion was acquired by Clearwater Analytics in April 2025 and no longer operates as an independent company. Thomas Kim served as CEO from March 2020 to August 2022. He was succeeded by Oleg Movchan, who was named interim CEO in August 2022 and became permanent CEO in December 2022, leading the company through the Clearwater acquisition.

What is Thomas Kim’s net worth in 2026?

Thomas Kim’s net worth is estimated at approximately $7–15 million USD as of 2026, based on his Enfusion stock holdings of approximately 897,870 shares (worth about $10.1 million at the Clearwater merger price of $11.25/share), plus accumulated career earnings and his current compensation as CEO of Zone & Co.

What was Enfusion CEO Thomas Kim’s salary?

Thomas Kim’s base salary at Enfusion was approximately $650,000 per year. His total compensation, including stock awards and incentives, was estimated at approximately $4.1 million for fiscal year 2021. Upon his resignation in August 2022, he received a severance payment of $325,000 (six months’ base salary).

What is Thomas Kim’s email address?

Thomas Kim’s former Enfusion email was [email protected], which is no longer active. He can be reached via Twitter/X at @tkimny or through his LinkedIn profile. He is currently CEO of Zone & Co.

What happened to Enfusion?

Enfusion was acquired by Clearwater Analytics (NYSE: CWAN) for approximately $1.5 billion. The deal was announced on January 13, 2025, and closed on April 21, 2025. Enfusion shareholders received $11.25 per share ($5.85 in cash + $5.40 in Clearwater stock). ENFN was delisted from the NYSE, and Enfusion now operates as part of Clearwater Analytics.

Where is Thomas Kim now?

Since May 2023, Thomas Kim has served as CEO of Zone & Co, a global SaaS company that provides cloud-based enterprise financial automation solutions built natively on Oracle NetSuite. Under his leadership, Zone & Co experienced nearly 50% revenue growth in 2023 and welcomed over 1,500 new customers across Europe, Australia, and North America.

Article last updated:January 2026March 2, 2026

Disclaimer: All information presented in this article has been compiled from publicly available sources, including SEC filings, official company press releases, and reputable news outlets. Compensation figures are estimates based on proxy filings and public records. Net worth figures are estimates and may vary by source. This content is provided for informational purposes only and does not constitute financial or investment advice.